Loading…
Current status of proton pump inhibitor use in Japanese elderly patients with non-valvular atrial fibrillation: A subanalysis of the ANAFIE Registry
The real-world status of proton pump inhibitor (PPI) use in patients with atrial fibrillation (AF) receiving antithrombotic treatment is largely unknown. The All Nippon AF In the Elderly (ANAFIE) Registry, a prospective, multicenter, observational study, aimed to determine treatment patterns, risk f...
Saved in:
| Published in: | PloS one 2020-11, Vol.15 (11), p.e0240859 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c692t-abe105246eb3e4501b8a9318cf84e501214f55414a8065d02c12cce8aa7ab5e23 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c692t-abe105246eb3e4501b8a9318cf84e501214f55414a8065d02c12cce8aa7ab5e23 |
| container_end_page | |
| container_issue | 11 |
| container_start_page | e0240859 |
| container_title | PloS one |
| container_volume | 15 |
| creator | Mizokami, Yuji Yamamoto, Takatsugu Atarashi, Hirotsugu Yamashita, Takeshi Akao, Masaharu Ikeda, Takanori Koretsune, Yukihiro Okumura, Ken Shimizu, Wataru Tsutsui, Hiroyuki Toyoda, Kazunori Hirayama, Atsushi Yasaka, Masahiro Yamaguchi, Takenori Teramukai, Satoshi Kimura, Tetsuya Kaburagi, Jumpei Takita, Atsushi Inoue, Hiroshi |
| description | The real-world status of proton pump inhibitor (PPI) use in patients with atrial fibrillation (AF) receiving antithrombotic treatment is largely unknown. The All Nippon AF In the Elderly (ANAFIE) Registry, a prospective, multicenter, observational study, aimed to determine treatment patterns, risk factors, and outcomes among elderly (aged ≥75 years) Japanese non-valvular AF (NVAF) patients in the real-world clinical setting. The present subanalysis of the ANAFIE Registry determined the PPI prescription status of 32,490 elderly Japanese NVAF patients. Patients were stratified by PPI use (PPI+) or no PPI use (PPI-). Risk scores for stroke (CHADS2, CHA2DS2-VASc) and bleeding (HAS-BLED), anticoagulant use, time in therapeutic range (TTR) for warfarin, and anticoagulant/antiplatelet combination use were evaluated. PPIs were used in 11,981 (36.9%) patients. Compared with the PPI- group, the PPI+ group included a greater proportion of female patients (45.2% vs 41.3%; P |
| doi_str_mv | 10.1371/journal.pone.0240859 |
| format | article |
| fullrecord | <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_2457962696</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A640707188</galeid><doaj_id>oai_doaj_org_article_aa6cbf09894f4b57aca8d2c001c89b2f</doaj_id><sourcerecordid>A640707188</sourcerecordid><originalsourceid>FETCH-LOGICAL-c692t-abe105246eb3e4501b8a9318cf84e501214f55414a8065d02c12cce8aa7ab5e23</originalsourceid><addsrcrecordid>eNqNk12L1DAUhoso7rr6D0QDguDFjEmapq0XwjDs6sjiwvpxG07TdJol09QkHZ3_4Q82s9NdpqAgucjX8745vOQkyXOC5yTNydsbO7gOzLy3nZpjynCRlQ-SU1KmdMYpTh8erU-SJ97fYJylBeePk5M0JRkpeXma_F4OzqkuIB8gDB7ZBvXOBtuhftj0SHetrnSwDg1exR36BD10Kq6VqZUzO9RD0FHv0U8dWtTZbrYFsx0MOATBaTCo0ZXTxkTOdu_QAvmhglj4zuvb50Kr0OLz4mJ1jq7VWvvgdk-TRw0Yr56N81ny7eL86_Lj7PLqw2q5uJxJXtIwg0oRnFHGVZUqlmFSFVCmpJBNwVTcUsKaLGOEQYF5VmMqCZVSFQA5VJmi6Vny8uDbG-vFGKgXlGV5ySkveSRWB6K2cCN6pzfgdsKCFrcH1q0FuKClUQKAy6rBZVGyhlVZDhKKmkqMiSzKijbR6_342lBtVC1jag7MxHR60-lWrO1W5JwxnLFo8Go0cPbHoHz4R8kjtYZYle4aG83kRnspFpzhHOekKCI1_wsVR602WsYv1eh4PhG8mQgiE9SvsIbBe7H6cv3_7NX3Kfv6iG0VmNB6a4b9b_FTkB1A6az3TjX3yREs9h1xl4bYd4QYOyLKXhynfi-6a4H0D4GQCPM</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2457962696</pqid></control><display><type>article</type><title>Current status of proton pump inhibitor use in Japanese elderly patients with non-valvular atrial fibrillation: A subanalysis of the ANAFIE Registry</title><source>PubMed (Medline)</source><source>ProQuest - Publicly Available Content Database</source><creator>Mizokami, Yuji ; Yamamoto, Takatsugu ; Atarashi, Hirotsugu ; Yamashita, Takeshi ; Akao, Masaharu ; Ikeda, Takanori ; Koretsune, Yukihiro ; Okumura, Ken ; Shimizu, Wataru ; Tsutsui, Hiroyuki ; Toyoda, Kazunori ; Hirayama, Atsushi ; Yasaka, Masahiro ; Yamaguchi, Takenori ; Teramukai, Satoshi ; Kimura, Tetsuya ; Kaburagi, Jumpei ; Takita, Atsushi ; Inoue, Hiroshi</creator><contributor>Ai, Tomohiko</contributor><creatorcontrib>Mizokami, Yuji ; Yamamoto, Takatsugu ; Atarashi, Hirotsugu ; Yamashita, Takeshi ; Akao, Masaharu ; Ikeda, Takanori ; Koretsune, Yukihiro ; Okumura, Ken ; Shimizu, Wataru ; Tsutsui, Hiroyuki ; Toyoda, Kazunori ; Hirayama, Atsushi ; Yasaka, Masahiro ; Yamaguchi, Takenori ; Teramukai, Satoshi ; Kimura, Tetsuya ; Kaburagi, Jumpei ; Takita, Atsushi ; Inoue, Hiroshi ; Ai, Tomohiko</creatorcontrib><description>The real-world status of proton pump inhibitor (PPI) use in patients with atrial fibrillation (AF) receiving antithrombotic treatment is largely unknown. The All Nippon AF In the Elderly (ANAFIE) Registry, a prospective, multicenter, observational study, aimed to determine treatment patterns, risk factors, and outcomes among elderly (aged ≥75 years) Japanese non-valvular AF (NVAF) patients in the real-world clinical setting. The present subanalysis of the ANAFIE Registry determined the PPI prescription status of 32,490 elderly Japanese NVAF patients. Patients were stratified by PPI use (PPI+) or no PPI use (PPI-). Risk scores for stroke (CHADS2, CHA2DS2-VASc) and bleeding (HAS-BLED), anticoagulant use, time in therapeutic range (TTR) for warfarin, and anticoagulant/antiplatelet combination use were evaluated. PPIs were used in 11,981 (36.9%) patients. Compared with the PPI- group, the PPI+ group included a greater proportion of female patients (45.2% vs 41.3%; P <0.0001) and had significantly higher CHADS2, CHA2DS2-VASc, and HAS-BLED scores (P <0.0001 for each) as well as higher prevalences of several comorbidities. In the PPI+ group, 54.6% of patients did not have gastrointestinal (GI) disorders and were likely prescribed a PPI to prevent GI bleeding events. Most of the patients with a GI disorder in the PPI+ group had reflux esophagitis. Compared with patients not receiving anticoagulants, a significantly higher proportion of patients receiving anticoagulants received PPIs. For patients receiving anticoagulants, antiplatelet drugs, and both drugs, rates of PPI use were 34.1%, 44.1%, and 53.5%, respectively (P <0.01). Although the rate of PPI use was the highest for NVAF patients receiving both antiplatelet and anticoagulants, no clear differences were observed in the anticoagulants used. These data suggest that PPIs were actively prescribed in high-risk cases and may have been used to prevent GI bleeding among elderly NVAF patients receiving antithrombotic drugs. Trial registration: UMIN000024006.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0240859</identifier><identifier>PMID: 33151969</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Aged ; Aged, 80 and over ; Anticoagulants ; Anticoagulants - administration & dosage ; Anticoagulants - adverse effects ; Anticoagulants - therapeutic use ; Antiplatelet therapy ; Atrial fibrillation ; Atrial Fibrillation - complications ; Atrial Fibrillation - drug therapy ; Biology and Life Sciences ; Bleeding ; Cardiac arrhythmia ; Cohort Studies ; Complications and side effects ; Drug therapy ; Drug Therapy, Combination ; Drugs ; Elderly patients ; Esophagitis ; Female ; Fibrillation ; Fibrinolytic agents ; Gastrointestinal hemorrhage ; Health risks ; Hemorrhage - epidemiology ; Hemorrhage - etiology ; Hemorrhage - prevention & control ; Hospitals ; Humans ; Inhibitors ; Japan - epidemiology ; Male ; Medicine and Health Sciences ; Mortality ; Older people ; Patients ; Platelet Aggregation Inhibitors - administration & dosage ; Platelet Aggregation Inhibitors - adverse effects ; Platelet Aggregation Inhibitors - therapeutic use ; Prevention ; Prospective Studies ; Proton pump inhibitors ; Proton Pump Inhibitors - administration & dosage ; Proton Pump Inhibitors - therapeutic use ; Protons ; Registries ; Risk analysis ; Risk Factors ; Standard deviation ; Stroke ; Stroke - epidemiology ; Stroke - etiology ; Stroke - prevention & control ; Warfarin</subject><ispartof>PloS one, 2020-11, Vol.15 (11), p.e0240859</ispartof><rights>COPYRIGHT 2020 Public Library of Science</rights><rights>2020 Mizokami et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2020 Mizokami et al 2020 Mizokami et al</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c692t-abe105246eb3e4501b8a9318cf84e501214f55414a8065d02c12cce8aa7ab5e23</citedby><cites>FETCH-LOGICAL-c692t-abe105246eb3e4501b8a9318cf84e501214f55414a8065d02c12cce8aa7ab5e23</cites><orcidid>0000-0001-7425-823X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2457962696/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2457962696?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,315,733,786,790,891,25783,27957,27958,37047,44625,53827,53829,75483</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33151969$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Ai, Tomohiko</contributor><creatorcontrib>Mizokami, Yuji</creatorcontrib><creatorcontrib>Yamamoto, Takatsugu</creatorcontrib><creatorcontrib>Atarashi, Hirotsugu</creatorcontrib><creatorcontrib>Yamashita, Takeshi</creatorcontrib><creatorcontrib>Akao, Masaharu</creatorcontrib><creatorcontrib>Ikeda, Takanori</creatorcontrib><creatorcontrib>Koretsune, Yukihiro</creatorcontrib><creatorcontrib>Okumura, Ken</creatorcontrib><creatorcontrib>Shimizu, Wataru</creatorcontrib><creatorcontrib>Tsutsui, Hiroyuki</creatorcontrib><creatorcontrib>Toyoda, Kazunori</creatorcontrib><creatorcontrib>Hirayama, Atsushi</creatorcontrib><creatorcontrib>Yasaka, Masahiro</creatorcontrib><creatorcontrib>Yamaguchi, Takenori</creatorcontrib><creatorcontrib>Teramukai, Satoshi</creatorcontrib><creatorcontrib>Kimura, Tetsuya</creatorcontrib><creatorcontrib>Kaburagi, Jumpei</creatorcontrib><creatorcontrib>Takita, Atsushi</creatorcontrib><creatorcontrib>Inoue, Hiroshi</creatorcontrib><title>Current status of proton pump inhibitor use in Japanese elderly patients with non-valvular atrial fibrillation: A subanalysis of the ANAFIE Registry</title><title>PloS one</title><addtitle>PLoS One</addtitle><description>The real-world status of proton pump inhibitor (PPI) use in patients with atrial fibrillation (AF) receiving antithrombotic treatment is largely unknown. The All Nippon AF In the Elderly (ANAFIE) Registry, a prospective, multicenter, observational study, aimed to determine treatment patterns, risk factors, and outcomes among elderly (aged ≥75 years) Japanese non-valvular AF (NVAF) patients in the real-world clinical setting. The present subanalysis of the ANAFIE Registry determined the PPI prescription status of 32,490 elderly Japanese NVAF patients. Patients were stratified by PPI use (PPI+) or no PPI use (PPI-). Risk scores for stroke (CHADS2, CHA2DS2-VASc) and bleeding (HAS-BLED), anticoagulant use, time in therapeutic range (TTR) for warfarin, and anticoagulant/antiplatelet combination use were evaluated. PPIs were used in 11,981 (36.9%) patients. Compared with the PPI- group, the PPI+ group included a greater proportion of female patients (45.2% vs 41.3%; P <0.0001) and had significantly higher CHADS2, CHA2DS2-VASc, and HAS-BLED scores (P <0.0001 for each) as well as higher prevalences of several comorbidities. In the PPI+ group, 54.6% of patients did not have gastrointestinal (GI) disorders and were likely prescribed a PPI to prevent GI bleeding events. Most of the patients with a GI disorder in the PPI+ group had reflux esophagitis. Compared with patients not receiving anticoagulants, a significantly higher proportion of patients receiving anticoagulants received PPIs. For patients receiving anticoagulants, antiplatelet drugs, and both drugs, rates of PPI use were 34.1%, 44.1%, and 53.5%, respectively (P <0.01). Although the rate of PPI use was the highest for NVAF patients receiving both antiplatelet and anticoagulants, no clear differences were observed in the anticoagulants used. These data suggest that PPIs were actively prescribed in high-risk cases and may have been used to prevent GI bleeding among elderly NVAF patients receiving antithrombotic drugs. Trial registration: UMIN000024006.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Anticoagulants</subject><subject>Anticoagulants - administration & dosage</subject><subject>Anticoagulants - adverse effects</subject><subject>Anticoagulants - therapeutic use</subject><subject>Antiplatelet therapy</subject><subject>Atrial fibrillation</subject><subject>Atrial Fibrillation - complications</subject><subject>Atrial Fibrillation - drug therapy</subject><subject>Biology and Life Sciences</subject><subject>Bleeding</subject><subject>Cardiac arrhythmia</subject><subject>Cohort Studies</subject><subject>Complications and side effects</subject><subject>Drug therapy</subject><subject>Drug Therapy, Combination</subject><subject>Drugs</subject><subject>Elderly patients</subject><subject>Esophagitis</subject><subject>Female</subject><subject>Fibrillation</subject><subject>Fibrinolytic agents</subject><subject>Gastrointestinal hemorrhage</subject><subject>Health risks</subject><subject>Hemorrhage - epidemiology</subject><subject>Hemorrhage - etiology</subject><subject>Hemorrhage - prevention & control</subject><subject>Hospitals</subject><subject>Humans</subject><subject>Inhibitors</subject><subject>Japan - epidemiology</subject><subject>Male</subject><subject>Medicine and Health Sciences</subject><subject>Mortality</subject><subject>Older people</subject><subject>Patients</subject><subject>Platelet Aggregation Inhibitors - administration & dosage</subject><subject>Platelet Aggregation Inhibitors - adverse effects</subject><subject>Platelet Aggregation Inhibitors - therapeutic use</subject><subject>Prevention</subject><subject>Prospective Studies</subject><subject>Proton pump inhibitors</subject><subject>Proton Pump Inhibitors - administration & dosage</subject><subject>Proton Pump Inhibitors - therapeutic use</subject><subject>Protons</subject><subject>Registries</subject><subject>Risk analysis</subject><subject>Risk Factors</subject><subject>Standard deviation</subject><subject>Stroke</subject><subject>Stroke - epidemiology</subject><subject>Stroke - etiology</subject><subject>Stroke - prevention & control</subject><subject>Warfarin</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNqNk12L1DAUhoso7rr6D0QDguDFjEmapq0XwjDs6sjiwvpxG07TdJol09QkHZ3_4Q82s9NdpqAgucjX8745vOQkyXOC5yTNydsbO7gOzLy3nZpjynCRlQ-SU1KmdMYpTh8erU-SJ97fYJylBeePk5M0JRkpeXma_F4OzqkuIB8gDB7ZBvXOBtuhftj0SHetrnSwDg1exR36BD10Kq6VqZUzO9RD0FHv0U8dWtTZbrYFsx0MOATBaTCo0ZXTxkTOdu_QAvmhglj4zuvb50Kr0OLz4mJ1jq7VWvvgdk-TRw0Yr56N81ny7eL86_Lj7PLqw2q5uJxJXtIwg0oRnFHGVZUqlmFSFVCmpJBNwVTcUsKaLGOEQYF5VmMqCZVSFQA5VJmi6Vny8uDbG-vFGKgXlGV5ySkveSRWB6K2cCN6pzfgdsKCFrcH1q0FuKClUQKAy6rBZVGyhlVZDhKKmkqMiSzKijbR6_342lBtVC1jag7MxHR60-lWrO1W5JwxnLFo8Go0cPbHoHz4R8kjtYZYle4aG83kRnspFpzhHOekKCI1_wsVR602WsYv1eh4PhG8mQgiE9SvsIbBe7H6cv3_7NX3Kfv6iG0VmNB6a4b9b_FTkB1A6az3TjX3yREs9h1xl4bYd4QYOyLKXhynfi-6a4H0D4GQCPM</recordid><startdate>20201105</startdate><enddate>20201105</enddate><creator>Mizokami, Yuji</creator><creator>Yamamoto, Takatsugu</creator><creator>Atarashi, Hirotsugu</creator><creator>Yamashita, Takeshi</creator><creator>Akao, Masaharu</creator><creator>Ikeda, Takanori</creator><creator>Koretsune, Yukihiro</creator><creator>Okumura, Ken</creator><creator>Shimizu, Wataru</creator><creator>Tsutsui, Hiroyuki</creator><creator>Toyoda, Kazunori</creator><creator>Hirayama, Atsushi</creator><creator>Yasaka, Masahiro</creator><creator>Yamaguchi, Takenori</creator><creator>Teramukai, Satoshi</creator><creator>Kimura, Tetsuya</creator><creator>Kaburagi, Jumpei</creator><creator>Takita, Atsushi</creator><creator>Inoue, Hiroshi</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0001-7425-823X</orcidid></search><sort><creationdate>20201105</creationdate><title>Current status of proton pump inhibitor use in Japanese elderly patients with non-valvular atrial fibrillation: A subanalysis of the ANAFIE Registry</title><author>Mizokami, Yuji ; Yamamoto, Takatsugu ; Atarashi, Hirotsugu ; Yamashita, Takeshi ; Akao, Masaharu ; Ikeda, Takanori ; Koretsune, Yukihiro ; Okumura, Ken ; Shimizu, Wataru ; Tsutsui, Hiroyuki ; Toyoda, Kazunori ; Hirayama, Atsushi ; Yasaka, Masahiro ; Yamaguchi, Takenori ; Teramukai, Satoshi ; Kimura, Tetsuya ; Kaburagi, Jumpei ; Takita, Atsushi ; Inoue, Hiroshi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c692t-abe105246eb3e4501b8a9318cf84e501214f55414a8065d02c12cce8aa7ab5e23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Anticoagulants</topic><topic>Anticoagulants - administration & dosage</topic><topic>Anticoagulants - adverse effects</topic><topic>Anticoagulants - therapeutic use</topic><topic>Antiplatelet therapy</topic><topic>Atrial fibrillation</topic><topic>Atrial Fibrillation - complications</topic><topic>Atrial Fibrillation - drug therapy</topic><topic>Biology and Life Sciences</topic><topic>Bleeding</topic><topic>Cardiac arrhythmia</topic><topic>Cohort Studies</topic><topic>Complications and side effects</topic><topic>Drug therapy</topic><topic>Drug Therapy, Combination</topic><topic>Drugs</topic><topic>Elderly patients</topic><topic>Esophagitis</topic><topic>Female</topic><topic>Fibrillation</topic><topic>Fibrinolytic agents</topic><topic>Gastrointestinal hemorrhage</topic><topic>Health risks</topic><topic>Hemorrhage - epidemiology</topic><topic>Hemorrhage - etiology</topic><topic>Hemorrhage - prevention & control</topic><topic>Hospitals</topic><topic>Humans</topic><topic>Inhibitors</topic><topic>Japan - epidemiology</topic><topic>Male</topic><topic>Medicine and Health Sciences</topic><topic>Mortality</topic><topic>Older people</topic><topic>Patients</topic><topic>Platelet Aggregation Inhibitors - administration & dosage</topic><topic>Platelet Aggregation Inhibitors - adverse effects</topic><topic>Platelet Aggregation Inhibitors - therapeutic use</topic><topic>Prevention</topic><topic>Prospective Studies</topic><topic>Proton pump inhibitors</topic><topic>Proton Pump Inhibitors - administration & dosage</topic><topic>Proton Pump Inhibitors - therapeutic use</topic><topic>Protons</topic><topic>Registries</topic><topic>Risk analysis</topic><topic>Risk Factors</topic><topic>Standard deviation</topic><topic>Stroke</topic><topic>Stroke - epidemiology</topic><topic>Stroke - etiology</topic><topic>Stroke - prevention & control</topic><topic>Warfarin</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mizokami, Yuji</creatorcontrib><creatorcontrib>Yamamoto, Takatsugu</creatorcontrib><creatorcontrib>Atarashi, Hirotsugu</creatorcontrib><creatorcontrib>Yamashita, Takeshi</creatorcontrib><creatorcontrib>Akao, Masaharu</creatorcontrib><creatorcontrib>Ikeda, Takanori</creatorcontrib><creatorcontrib>Koretsune, Yukihiro</creatorcontrib><creatorcontrib>Okumura, Ken</creatorcontrib><creatorcontrib>Shimizu, Wataru</creatorcontrib><creatorcontrib>Tsutsui, Hiroyuki</creatorcontrib><creatorcontrib>Toyoda, Kazunori</creatorcontrib><creatorcontrib>Hirayama, Atsushi</creatorcontrib><creatorcontrib>Yasaka, Masahiro</creatorcontrib><creatorcontrib>Yamaguchi, Takenori</creatorcontrib><creatorcontrib>Teramukai, Satoshi</creatorcontrib><creatorcontrib>Kimura, Tetsuya</creatorcontrib><creatorcontrib>Kaburagi, Jumpei</creatorcontrib><creatorcontrib>Takita, Atsushi</creatorcontrib><creatorcontrib>Inoue, Hiroshi</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Opposing Viewpoints</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Proquest Nursing & Allied Health Source</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological & Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>ProQuest Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science & Engineering Collection</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>Advanced Technologies & Aerospace Database (1962 - current)</collection><collection>ProQuest Agriculture & Environmental Science Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection (Proquest) (PQ_SDU_P3)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Materials Science Database</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Meteorological & Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>Biological Sciences</collection><collection>Agriculture Science Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>ProQuest Engineering Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials Science Collection</collection><collection>ProQuest - Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Engineering Collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mizokami, Yuji</au><au>Yamamoto, Takatsugu</au><au>Atarashi, Hirotsugu</au><au>Yamashita, Takeshi</au><au>Akao, Masaharu</au><au>Ikeda, Takanori</au><au>Koretsune, Yukihiro</au><au>Okumura, Ken</au><au>Shimizu, Wataru</au><au>Tsutsui, Hiroyuki</au><au>Toyoda, Kazunori</au><au>Hirayama, Atsushi</au><au>Yasaka, Masahiro</au><au>Yamaguchi, Takenori</au><au>Teramukai, Satoshi</au><au>Kimura, Tetsuya</au><au>Kaburagi, Jumpei</au><au>Takita, Atsushi</au><au>Inoue, Hiroshi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Current status of proton pump inhibitor use in Japanese elderly patients with non-valvular atrial fibrillation: A subanalysis of the ANAFIE Registry</atitle><jtitle>PloS one</jtitle><addtitle>PLoS One</addtitle><date>2020-11-05</date><risdate>2020</risdate><volume>15</volume><issue>11</issue><spage>e0240859</spage><pages>e0240859-</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><notes>Competing Interests: The authors have read the journal’s policy and have the following potential competing interests: Tetsuya Kimura, Jumpei Kaburagi, and Atsushi Takita are paid employees of Daiichi Sankyo Co., Ltd., Tokyo, Japan. Yuji Mizokami received research funding from Daiichi Sankyo, and remuneration from Daiichi Sankyo. Takatsugu Yamamoto received remuneration from Nippon Boehringer Ingelheim, Bristol-Myers Squibb, Takeda Pharmaceutical, Otsuka Pharmaceutical, and AstraZeneca. Hirotsugu Atarashi received remuneration from Daiichi Sankyo. Takeshi Yamashita received research funding from Bristol-Myers Squibb, Bayer, and Daiichi Sankyo, manuscript fees from Daiichi Sankyo and Bristol-Myers Squibb, and remuneration from Daiichi Sankyo, Bayer, Pfizer Japan, and Bristol-Myers Squibb. Masaharu Akao received research funding from Bayer and Daiichi Sankyo, and remuneration from Bristol-Myers Squibb, Nippon Boehringer Ingelheim, Bayer, and Daiichi Sankyo. Takanori Ikeda received research funding from Daiichi Sankyo and Bayer, and remuneration from Daiichi Sankyo, Bayer, Nippon Boehringer Ingelheim, and Bristol-Myers Squibb. Yukihiro Koretsune received remuneration from Daiichi Sankyo, Bayer, and Nippon Boehringer Ingelheim. Ken Okumura received remuneration from Nippon Boehringer Ingelheim, Daiichi Sankyo, Johnson & Johnson, and Medtronic. Wataru Shimizu received research funding from Bristol-Myers Squibb, Daiichi Sankyo, and Nippon Boehringer Ingelheim, and patent royalties/licensing fees from Daiichi Sankyo, Pfizer Japan, Bristol-Myers Squibb, Bayer, and Nippon Boehringer Ingelheim. Hiroyuki Tsutsui received research funding from Daiichi Sankyo and Nippon Boehringer Ingelheim, remuneration from Daiichi Sankyo, Bayer, Nippon Boehringer Ingelheim, and Pfizer Japan, scholarship funding from Daiichi Sankyo, and consultancy fees from Pfizer Japan, Bayer, and Nippon Boehringer Ingelheim. Kazunori Toyoda received remuneration from Daiichi Sankyo, Bayer, Bristol-Myers Squibb, and Nippon Boehringer Ingelheim. Atsushi Hirayama participated in a course endowed by Boston Scientific Japan, and has received research funding from Daiichi Sankyo and Bayer, and remuneration from Bayer, Daiichi Sankyo, Bristol-Myers Squibb, and Nippon Boehringer Ingelheim. Masahiro Yasaka received research funding from Nippon Boehringer Ingelheim, and remuneration from Nippon Boehringer Ingelheim, Daiichi Sankyo, Bayer, Bristol-Myers Squibb, and Pfizer Japan. Takenori Yamaguchi acted as an Advisory Board member of Daiichi Sankyo and received remuneration from Daiichi Sankyo and Bristol-Myers Squibb. Satoshi Teramukai received research funding from Nippon Boehringer Ingelheim and remuneration from Daiichi Sankyo. Tetsuya Kimura, Jumpei Kaburagi, and Atsushi Takita are employees of Daiichi Sankyo. Hiroshi Inoue received remuneration from Daiichi Sankyo, Bayer, Bristol-Myers Squibb, and Nippon Boehringer Ingelheim. This does not alter our adherence to PLOS ONE policies on sharing data and materials. The authors would like to declare the following patents/patent applications associated with this research: Daiichi Sankyo has launched Nexium® (esomeprazole magnesium hydrate) which is one of the proton pump inhibitors.</notes><abstract>The real-world status of proton pump inhibitor (PPI) use in patients with atrial fibrillation (AF) receiving antithrombotic treatment is largely unknown. The All Nippon AF In the Elderly (ANAFIE) Registry, a prospective, multicenter, observational study, aimed to determine treatment patterns, risk factors, and outcomes among elderly (aged ≥75 years) Japanese non-valvular AF (NVAF) patients in the real-world clinical setting. The present subanalysis of the ANAFIE Registry determined the PPI prescription status of 32,490 elderly Japanese NVAF patients. Patients were stratified by PPI use (PPI+) or no PPI use (PPI-). Risk scores for stroke (CHADS2, CHA2DS2-VASc) and bleeding (HAS-BLED), anticoagulant use, time in therapeutic range (TTR) for warfarin, and anticoagulant/antiplatelet combination use were evaluated. PPIs were used in 11,981 (36.9%) patients. Compared with the PPI- group, the PPI+ group included a greater proportion of female patients (45.2% vs 41.3%; P <0.0001) and had significantly higher CHADS2, CHA2DS2-VASc, and HAS-BLED scores (P <0.0001 for each) as well as higher prevalences of several comorbidities. In the PPI+ group, 54.6% of patients did not have gastrointestinal (GI) disorders and were likely prescribed a PPI to prevent GI bleeding events. Most of the patients with a GI disorder in the PPI+ group had reflux esophagitis. Compared with patients not receiving anticoagulants, a significantly higher proportion of patients receiving anticoagulants received PPIs. For patients receiving anticoagulants, antiplatelet drugs, and both drugs, rates of PPI use were 34.1%, 44.1%, and 53.5%, respectively (P <0.01). Although the rate of PPI use was the highest for NVAF patients receiving both antiplatelet and anticoagulants, no clear differences were observed in the anticoagulants used. These data suggest that PPIs were actively prescribed in high-risk cases and may have been used to prevent GI bleeding among elderly NVAF patients receiving antithrombotic drugs. Trial registration: UMIN000024006.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>33151969</pmid><doi>10.1371/journal.pone.0240859</doi><tpages>e0240859</tpages><orcidid>https://orcid.org/0000-0001-7425-823X</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1932-6203 |
| ispartof | PloS one, 2020-11, Vol.15 (11), p.e0240859 |
| issn | 1932-6203 1932-6203 |
| language | eng |
| recordid | cdi_plos_journals_2457962696 |
| source | PubMed (Medline); ProQuest - Publicly Available Content Database |
| subjects | Aged Aged, 80 and over Anticoagulants Anticoagulants - administration & dosage Anticoagulants - adverse effects Anticoagulants - therapeutic use Antiplatelet therapy Atrial fibrillation Atrial Fibrillation - complications Atrial Fibrillation - drug therapy Biology and Life Sciences Bleeding Cardiac arrhythmia Cohort Studies Complications and side effects Drug therapy Drug Therapy, Combination Drugs Elderly patients Esophagitis Female Fibrillation Fibrinolytic agents Gastrointestinal hemorrhage Health risks Hemorrhage - epidemiology Hemorrhage - etiology Hemorrhage - prevention & control Hospitals Humans Inhibitors Japan - epidemiology Male Medicine and Health Sciences Mortality Older people Patients Platelet Aggregation Inhibitors - administration & dosage Platelet Aggregation Inhibitors - adverse effects Platelet Aggregation Inhibitors - therapeutic use Prevention Prospective Studies Proton pump inhibitors Proton Pump Inhibitors - administration & dosage Proton Pump Inhibitors - therapeutic use Protons Registries Risk analysis Risk Factors Standard deviation Stroke Stroke - epidemiology Stroke - etiology Stroke - prevention & control Warfarin |
| title | Current status of proton pump inhibitor use in Japanese elderly patients with non-valvular atrial fibrillation: A subanalysis of the ANAFIE Registry |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-09-22T16%3A28%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Current%20status%20of%20proton%20pump%20inhibitor%20use%20in%20Japanese%20elderly%20patients%20with%20non-valvular%20atrial%20fibrillation:%20A%20subanalysis%20of%20the%20ANAFIE%20Registry&rft.jtitle=PloS%20one&rft.au=Mizokami,%20Yuji&rft.date=2020-11-05&rft.volume=15&rft.issue=11&rft.spage=e0240859&rft.pages=e0240859-&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0240859&rft_dat=%3Cgale_plos_%3EA640707188%3C/gale_plos_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c692t-abe105246eb3e4501b8a9318cf84e501214f55414a8065d02c12cce8aa7ab5e23%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2457962696&rft_id=info:pmid/33151969&rft_galeid=A640707188&rfr_iscdi=true |